Spectral Medical Provides Tigris Trial Update - The Globe and Mail
Spectral Medical Inc. updates on Tigris trial, a Phase 3 study for PMX in treating endotoxemia and septic shock, with 101 patients enrolled by Q1 2024. Aiming for full enrollment of 150 patients, Spectral hosted an Investigator Meeting to support trial progress. PMX, a therapeutic device for septic shock, is under U.S. FDA review.
Reference News
Spectral Medical Provides Tigris Trial Update - The Globe and Mail
Spectral Medical Inc. updates on Tigris trial, a Phase 3 study for PMX in treating endotoxemia and septic shock, with 101 patients enrolled by Q1 2024. Aiming for full enrollment of 150 patients, Spectral hosted an Investigator Meeting to support trial progress. PMX, a therapeutic device for septic shock, is under U.S. FDA review.